semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Life Stress Fatigue Pain Quality of Life Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the visit for the women of reproductive age Older than 30 years and younger than 65 years BMI ≤ 30 Score greater than 30 on the Cohen perceived stress scale PSS 14 Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits) Presenting an impact of stress on at least one of the following domains pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test Stable professional activity since at least 1 year  Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment Pregnant and/or breast-feeding women Any person who does not satisfy by definition the criteria Adult protected by the law Any history of psychiatric disease Any pathology in progress or active in the previous month Any administration of a dietary supplement in progress or in the previous month Any subject who within the 3 months following is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia Chronic Kidney Disease age > 18 written informed consent CKD stage 3-5 (eGFR <60 ml/min/1,73 m2) PTH 30-300 pg/ml Hb <10 g/dl >3 consecutive months Ferritin > 100 ng/ml transferrin saturation (TSAT) 20-40% mean corpuscular volume (MCV) 85-95% for patients treated with Ace-inhibitors or angiotensin receptor blockers, dose stable >3 months for patients treated with erythropoiesis-stimulating agents (ESA), dose stable >3 months  anemia due to non renal cause presence of malignancies, inflammatory or infectious disease >3 months pregnancy bleeding >6 months C-reactive protein (CRP) >1 mg/dl poorly controlled hypertension (PAS > 170 mmHG and PAD >100 mmHg) severe malnutrition hypercalcemia (>10,5 mg/dl) hyperphosphatemia (>5,5 mg/dl) surgical interventions >3 months
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depression Chronic Low Back Pain Meets DSM-IV for current major depressive disorder. 2. Participants must have a Quick Inventory of Depressive Symptoms (QIDS) score >11. 3. Chronic low back pain. Pain must be > 6 months duration, in the low back (lumbar region), present > ½ the days of the month, and, on average, be of at least a moderate level of severity in the last month (> 4 on an 11-point numerical rating of pain intensity ranging from 0 [no pain] to10 [worst pain imaginable]. Pain-related disability / functional impact of pain must be of at least moderate severity at the time of intake, determined by a score of at > 7 on the Roland Morris Disability Questionnaire (RMDQ; (Roland & Morris, 1983)) 4. Continued pain despite having attempted initial steps of PCP guideline-based care (Chou et al., 2007). Participants must have been under the care of a physician for low back pain for > 6 months and have already had > 2 trials of recommended medications (i.e., acetaminophen, NSAIDs, skeletal muscle relaxants, opioids, and/or benzodiazepines).This will be judged through chart review and interviews with patients & PCPs. 5. Antidepressant dose stable for previous 2 months. If the participant is taking an antidepressant, he/ she must have been on the same dose for the previous 2 months. 6. Aged 18 or older. 7. Have a PCP at one of our enrollment sites  Lifetime diagnosis of bipolar disorder, schizophrenia, or other chronic psychotic condition. 2. Current hazardous illicit drug or alcohol use assessed with the AUDIT and DUDIT. 3. Opiate misuse will be assessed with the COMM and via primary care chart review. 4. Suicidal ideation or behavior requiring immediate attention. 5. In psychotherapy or in a multidisciplinary pain management program at baseline. 6. Anticipate having surgery in the next 6 months. 7. Pain thought to be due to visceral disease, cancer, infection, or inflammatory arthritis or pain associated with severe or progressive neurological deficits. 8. Current pregnancy
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyper-reactive Malarial Splenomegaly Malaria Anaemia Defining features of HMS including chronic massive splenomegaly (at least 10 cm below the costal margin); serum Immunoglobulin M elevated more than 3.1 g/L and high malarial antibody titres (above 640) Evidence of the polyclonal nature of the lymphocytes by serum immunoglobulin free light chains Aged at least 18 years Haemoglobin level of > 5 mg/d  known allergy to chloroquine use of anti-malarial treatment within the preceding month suspected coexisting diseases in which glucocorticoids are contraindicated (e.g. diabetes mellitus, peptic ulcer disease or any acute infection as defined clinically), and splenomegaly secondary to known infectious or haematological causes
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fibrous Dysplasia of Bone fibrous dysplasia of bone previously treated with IV bisphosphonates persistent bone pain and increased bone remodeling  Chronic renal failure serious infectious diseases liver enzymes abnormality pregnancy dyslipidemia
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Sickle Cell Anemia Age >= 18 years of age 2. Diagnosis of homozygous sickle cell (SS) or S-beta thalassemia with at least two episodes of vaso-occlusive crises (VOC) requiring narcotics in each of the past 2 years. For part 2 can hemoglobin SC disease. 3. For females of reproductive age, use of contraception and negative pregnancy test  An additional hematologic diagnosis 2. Hemoglobin (Hgb) < 7gm/dL for part 1, < 6 gm/dL for part 2. 3. Asthma requiring medication 4. Liver function tests [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (BilliT) > three times upper normal limit for Part 1. 5. Chronic transfusion therapy, or transfusion within 2 months of enrollment. For part 2 anticipated need for simple or exchange transfusion during hospitalization. 6. VOC requiring narcotic therapy within the prior week or requiring hospitalization with discharge < 2 weeks prior to study enrollment for Part 1, for part 2 admission for VOC within 30 days. 7. Pregnancy or nursing 8. Receiving another investigational drug 9. Known allergy to NAC 10. Per subject's physician not medically stable enough to participate 11. Taking nitroglycerin, carbamazepine, or phosphodiesterase 5 (PDE5) inhibitors 12. Abnormal baseline coagulation tests (> 1.5 times normal limits) 13. Platelets <150,000/microliter for Part 1. 14. For part 2, already enrolled in study twice
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coronary Artery Disease Pain, Postoperative ≥ 18 years old non-emergent coronary artery bypass grafting surgery (on and off pump) median sternotomy  Concomitant cardiac procedures (e.g. aortic valve repair/replacement, mitral valve repair/replacement, aortic root replacements) Redo sternotomy < 50 kg (Exparel® is currently only approved in patients > 50 kg) Pregnant or nursing History of alcohol, narcotic or illicit drug abuse Participation in another study evaluating investigational medications within the past 30 days Taking narcotic analgesics within 3 days pre-operatively or perioperative stress-dose steroids Chronic non-cardiac pain (e.g. lower back pain, fibromyalgia) requiring narcotic analgesics Pre-operative mild liver insufficiency as defined by liver function tests [(i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST)] ≥ 1.5 times the upper limit of normal (ULN: ALT: 0-35 U/L, AST: 0-35 U/L, Alk Phos 35-105 U/L, Total bilirubin: 0-1.2 mg/dL) Pre-operative mild renal insufficiency (Cr ≥ 1.5 mg/dL)
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Application Site Discomfort Medical Device Discomfort Volunteers will be eligible for the study if they meet all of the below criteria American Society of Anesthesiologists (ASA) classification I or II years of age to a maximum of 70 years of age  Pre-existing parasthesia or neuropathy of any kind History of excessive alcohol consumption (> three drinks per night) Take analgesics on a regular basis History of any drug abuse Baseline systolic blood pressure ≥ 150 Baseline diastolic blood pressure ≥ 85 BMI ≥ 30 Pregnancy Allergic reaction to local anesthetic
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Postoperative Nausea Adverse Effects Opioid Analgesic Adverse Reaction Pain patients on postoperative head and neck oncologic surgery and 3 American Society of Anesthesiologists physical status moderate to severe postoperative pain elective surgery able to swallow tablets whole (not chewed, broken or crushed) in the immediate postoperative period after recovery of cognitive functions  pregnant or breastfeeding allergic to oxycodone and other opioids gastrectomized or colostomized asthmatics with severe organ dysfunction history or suspected paralytic ileus history psychiatric disorders severe respiratory depression patients who are receiving opioid analgesics in baseline history of abuse of alcohol and illicit drugs plasma glutamic oxaloacetic transaminase above 48 U / l (men) and 40 U / I (women) and / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U / I (women)
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Sickle Cell Disease Patients with Homozygous (HbSS) Sickle Cell Anemia Hb levels: >6g/dL <10g/dL Age : >18 years old Frequency of ER hospitalizations < 6x/yr for SCD pain events documented "medical history"  Patients, who are on chronic transfusion program, defined as regular transfusions every 2-8 weeks Allergic to Hydroxyurea History of clinical significant disease, as determined by the Investigator History of allergy or major allergic reaction considered to be clinically significant by the Investigator Screening assessments considered to be abnormal by the Investigator Patient has sever pulmonary hypertension (index >3 meters per sec) Donated blood within 60 days of screening or otherwise experienced blood loss of >250 mL within the same period Intending to begin new concomitant drug therapy or over-the-counter medication anytime from scree4nin to the time of administration of study drug
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Sickle Cell Disease Age 12 years or older Sickle cell disease, either homozygous sickle cell disease (HbSS), compound heterozygous sickle cell disease (HbSC), HbSβ0 or HbSβ+ thalassemia History of at least 1.0 painful crisis per year in the past 3 years (visit to medical facility is not required)  Chronic blood transfusion or transfusion in the preceding 3 months Painful crisis in the last 4 weeks (with respect to the moment of inclusion) Pregnancy, breast feeding or the desire to get pregnant in the following 7 months Known active gastric/duodenal ulcers Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or started on HC shorter then 6 months prior to study Known poor compliance in earlier trials regarding the completion of pain diaries Insufficient compliance in run-in period Known hypersensitivity to acetylcysteine or one of the other components of the study medication Use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months ('chronic pain')